Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

Patients with advanced or metastatic urothelial cancer who had had a response to platinum-based chemotherapy were randomly assigned to best supportive care alone or best supportive care plus avelumab (an anti–PD-L1 antibody) every 2 weeks until progression. Patients receiving avelumab had significan...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2020-09, Vol.383 (13), p.1218-1230
Hauptverfasser: Powles, Thomas, Park, Se Hoon, Voog, Eric, Caserta, Claudia, Valderrama, Begoña P, Gurney, Howard, Kalofonos, Haralabos, Radulović, Siniša, Demey, Wim, Ullén, Anders, Loriot, Yohann, Sridhar, Srikala S, Tsuchiya, Norihiko, Kopyltsov, Evgeny, Sternberg, Cora N, Bellmunt, Joaquim, Aragon-Ching, Jeanny B, Petrylak, Daniel P, Laliberte, Robert, Wang, Jing, Huang, Bo, Davis, Craig, Fowst, Camilla, Costa, Nuno, Blake-Haskins, John A, di Pietro, Alessandra, Grivas, Petros
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Patients with advanced or metastatic urothelial cancer who had had a response to platinum-based chemotherapy were randomly assigned to best supportive care alone or best supportive care plus avelumab (an anti–PD-L1 antibody) every 2 weeks until progression. Patients receiving avelumab had significantly longer overall survival (21 months) than those receiving only best supportive care (14 months).
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2002788